Clinical Trial Update: HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL [Phase 2]

View source ↗

Summary

This is an update on a Phase 2 clinical trial evaluating tafasitamab in combination with lenalidomide and rituximab in treatment-naive follicular lymphoma and m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING